Grufity logo
Grufity logo
DAWN

DAWN - Day One Biopharmaceuticals, Inc. Stock Price, Fair Value and News

$21.53 
Market Closed as of 24 Apr 2026, 04:00 pm ET

Price Targets

DAWN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DAWN Price Action

Last 7 days

0.3%

Last 30 days

0.8%

Last 90 days

80.2%

Trailing 12 Months

172.5%

DAWN RSI Chart

DAWN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DAWN Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

14.02

Price/Free Cashflow

-21.3

DAWN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

DAWN Fundamentals

DAWN Revenue

Revenue (TTM)

158.2M

Rev. Growth (Yr)

98.77%

Rev. Growth (Qtr)

34.99%

DAWN Earnings

Earnings (TTM)

-107.3B

Earnings Growth (Yr)

-12.33%

Earnings Growth (Qtr)

-543.5K%

DAWN Profitability

Return on Equity

-24.3K%

Return on Assets

-21.1K%

Free Cashflow Yield

-4.69%

DAWN Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

-1.04

Revenue & Growth

How Day One Biopharmaceuticals, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025159.7M185.5M131.5M158.2M
202418.1M22.9M111.3M133.3M
20238.2M11.4M14.8M17.2M
2022---4.7M
2021----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Day One Biopharmaceuticals, Inc.

DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
 CEO
 WEBSITEhttps://dayonebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES124

Day One Biopharmaceuticals, Inc. Frequently Asked Questions

DAWN is the stock ticker symbol of Day One Biopharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Apr 24 2026, market cap of Day One Biopharmaceuticals, Inc. is 2.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Apr 24 2026, DAWN's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 14.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DAWN PE ratio will change depending on the future growth rate expectations of investors.